Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’
Titel:
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’
Auteur:
Schöffski, P. Wozniak, A. Stacchiotti, S. Rutkowski, P. Blay, J.-Y. Lindner, L.H. Strauss, S.J. Anthoney, A. Duffaud, F. Richter, S. Grünwald, V. Leahy, M.G. Reichardt, P. Sufliarsky, J. van der Graaf, W.T. Sciot, R. Debiec-Rychter, M. van Cann, T. Marréaud, S. Lia, M. Raveloarivahy, T. Collette, L. Bauer, S.